JPWO2021089850A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021089850A5 JPWO2021089850A5 JP2022525998A JP2022525998A JPWO2021089850A5 JP WO2021089850 A5 JPWO2021089850 A5 JP WO2021089850A5 JP 2022525998 A JP2022525998 A JP 2022525998A JP 2022525998 A JP2022525998 A JP 2022525998A JP WO2021089850 A5 JPWO2021089850 A5 JP WO2021089850A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- region
- molar ratio
- antigen
- substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000006467 substitution reaction Methods 0.000 claims description 90
- 239000000427 antigen Substances 0.000 claims description 64
- 102000036639 antigens Human genes 0.000 claims description 64
- 108091007433 antigens Proteins 0.000 claims description 64
- 210000004027 cell Anatomy 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 13
- 239000004337 magnesium citrate Substances 0.000 claims description 10
- 210000004881 tumor cell Anatomy 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003981 vehicle Substances 0.000 claims description 6
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 4
- 108010065524 CD52 Antigen Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 210000000265 leukocyte Anatomy 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 3
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 3
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 210000003289 regulatory T cell Anatomy 0.000 claims description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000004981 tumor-associated macrophage Anatomy 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 8
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 22
- 238000000034 method Methods 0.000 description 18
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 16
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 16
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 16
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 16
- 230000004988 N-glycosylation Effects 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 6
- 239000001825 Polyoxyethene (8) stearate Substances 0.000 description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000001279 glycosylating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229950005972 urelumab Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201901296 | 2019-11-06 | ||
| DKPA201901296 | 2019-11-06 | ||
| PCT/EP2020/081389 WO2021089850A1 (en) | 2019-11-06 | 2020-11-06 | Antibody variant combinations and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023500701A JP2023500701A (ja) | 2023-01-10 |
| JP2023500701A5 JP2023500701A5 (https=) | 2023-11-10 |
| JPWO2021089850A5 true JPWO2021089850A5 (https=) | 2023-11-10 |
Family
ID=73449012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525998A Pending JP2023500701A (ja) | 2019-11-06 | 2020-11-06 | 抗体変種の組み合わせおよびその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220411529A1 (https=) |
| EP (1) | EP4055046A1 (https=) |
| JP (1) | JP2023500701A (https=) |
| WO (1) | WO2021089850A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3743440A1 (en) * | 2018-01-24 | 2020-12-02 | Genmab B.V. | Polypeptide variants and uses thereof |
| BR112020022179A2 (pt) | 2018-05-03 | 2021-02-02 | Genmab B.V. | primeiro anticorpo, anticorpo, composição, métodos para tratar um indivíduo tendo uma doença, para esgotar uma população de célula e para induzir a proliferação em uma população de célula, e, kit. |
| JP2024540951A (ja) * | 2021-10-20 | 2024-11-06 | ヤンセン バイオテツク，インコーポレーテツド | 増強されたエフェクター機能を有する生体合成バイパラトピック又は二重特異性結合分子 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| EP3424951A1 (en) | 2007-06-21 | 2019-01-09 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
| EP2376109B1 (en) | 2008-12-19 | 2019-01-23 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| EP2507381A4 (en) | 2009-12-04 | 2016-07-20 | Hoffmann La Roche | MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS |
| SG183542A1 (en) | 2010-03-12 | 2012-10-30 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| JP6055404B2 (ja) | 2010-06-15 | 2016-12-27 | ゲンマブ エー／エス | 組織因子に対するヒト抗体薬物結合体 |
| PL2606064T3 (pl) | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
| MX340556B (es) | 2010-08-24 | 2016-07-14 | Roche Glycart Ag | Anticuerpos biespecificos activables. |
| WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| SG10201602394QA (en) | 2011-03-29 | 2016-05-30 | Roche Glycart Ag | Antibody FC Variants |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| LT2794905T (lt) | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams |
| SI2838917T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul |
| BR112015000167B1 (pt) * | 2012-07-06 | 2021-11-23 | Genmab B.V. | Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante |
| EP2684896A1 (en) | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
| JP2015527366A (ja) | 2012-08-20 | 2015-09-17 | グリックニック インコーポレイテッド | 抗原結合および多価ｆｃガンマ受容体結合活性を有する分子 |
| KR20200024345A (ko) | 2013-01-10 | 2020-03-06 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
| CN106255704A (zh) | 2014-04-16 | 2016-12-21 | Ucb生物制药私人有限公司 | 多聚体Fc蛋白 |
| MA43365A (fr) | 2015-12-01 | 2018-10-10 | Genmab Bv | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci |
| WO2018031258A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
| EP3743440A1 (en) | 2018-01-24 | 2020-12-02 | Genmab B.V. | Polypeptide variants and uses thereof |
-
2020
- 2020-11-06 US US17/774,333 patent/US20220411529A1/en active Pending
- 2020-11-06 EP EP20807299.1A patent/EP4055046A1/en active Pending
- 2020-11-06 WO PCT/EP2020/081389 patent/WO2021089850A1/en not_active Ceased
- 2020-11-06 JP JP2022525998A patent/JP2023500701A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250340638A1 (en) | Cd3 binding antibodies | |
| US20230082273A1 (en) | Bispecific recombinant protein and use thereof | |
| JP4494977B2 (ja) | Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質 | |
| US12435154B2 (en) | Bispecific antibodies against CD3 and CD20 | |
| JP7543247B2 (ja) | ヒトＴｉｍ－３に対するモノクローナル抗体 | |
| RS64588B1 (sr) | Kombinacija anti-pd-1 antitela i bispecifičnih anti-cd20/anti-cd3 antitela za lečenje kancera | |
| JP7689116B2 (ja) | Ｐｄ１およびｖｅｇｆｒ２二重結合剤 | |
| JP2021522303A5 (https=) | ||
| IL266917B1 (en) | Conjugates of a drug and an antibody to the human prolactin receptor (prrl) and their use in the combined treatment of prlr-positive breast cancer | |
| CN115279791A (zh) | 靶向her2的抗原结合构建体及用途 | |
| CA3062479A1 (en) | Bispecific recombinant protein and use thereof | |
| EP4248995A1 (en) | Use of anti-ox40 antibody for treating tumors or cancers | |
| JPWO2021089850A5 (https=) | ||
| JPWO2019211472A5 (https=) | ||
| CN112672759B (zh) | 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途 | |
| RU2827062C1 (ru) | Антитело анти-pvrig протеин или фрагмент антитела и их использование | |
| WO2024124107A2 (en) | Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy | |
| Oostindie | Clustering: a rational design principle for potentiated antibod therapeutics | |
| RU2807216C2 (ru) | Антитела, связывающие cd3 | |
| HK40107381A (en) | Cd3 binding antibodies | |
| HK40078017A (en) | Cd3 binding antibodies | |
| WO2025119153A1 (zh) | 一种多特异性抗体的组合物及其制备方法和应用 | |
| HK40078017B (en) | Cd3 binding antibodies | |
| HK40081132A (en) | Antigen binding constructs targeting her2 and uses thereof | |
| HK40089030A (zh) | 针对cd3和cd20的双特异性抗体 |